The purpose of Cellaria’s in vitro cancer cell models is to accelerate clinical studies by facilitating the study of disease within specific and unique patient biology. We use our expertise in cell line growth, stabilization, and characterization to provide tools that answer directly to the requirements of those at the cutting edge of oncology research. While the models are our core product, we think hard about the information provided with them to ensure that researchers choose the most suitable model and use it productively from the get-go.
We sat down with CTO Dima Shvartsman, Ph.D to speak about his role within the company and the exciting potential for human health research using Cellaria's cell lines and cell models.
Offering researchers a diverse cohort of patient specific models to accelerate drug development.
A diverse patient cohort for non-small cell lung cancer
New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials
Cellaria scientists to present latest studies at
We are pleased to announce a grant collaboration with Dr. Bryan Spring, of Northeastern University. Recently, we sat down with Dr. Spring to understand the value sees with Cellaria cell models when compared to conventional cell lines for pancreatic and ovarian cancer. The ultimate goal of his lab is to reduce cancer recurrence and mortality by establishing new approaches for personalized medicine that address tumor heterogeneity, drug-resistance and molecular mechanisms of treatment.